Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Current Liabilities (2022 - 2025)

NewAmsterdam Pharma's Total Current Liabilities history spans 4 years, with the latest figure at $85.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 19.76% year-over-year to $85.8 million; the TTM value through Dec 2025 reached $85.8 million, down 19.76%, while the annual FY2025 figure was $85.8 million, 19.76% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $85.8 million at NewAmsterdam Pharma, up from $58.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $106.9 million in Q4 2024 and bottomed at $36.2 million in Q4 2022.
  • The 4-year median for Total Current Liabilities is $47.6 million (2023), against an average of $56.1 million.
  • The largest annual shift saw Total Current Liabilities surged 114.28% in 2024 before it crashed 31.5% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $36.2 million in 2022, then soared by 37.92% to $49.9 million in 2023, then soared by 114.28% to $106.9 million in 2024, then fell by 19.76% to $85.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Total Current Liabilities are $85.8 million (Q4 2025), $58.3 million (Q3 2025), and $36.5 million (Q2 2025).